28 results
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:18pm
interactions and confirmed by the SME office – Regulatory Science and Innovation Task Force. SME status provides reduced costs to the Company … innovation through in-licensing of new technologies and compositions of matter as appropriate. We intend to take advantage of any available data
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:11pm
interactions and confirmed by the SME office – Regulatory Science and Innovation Task Force. SME status provides reduced costs to the Company … internal innovation through in-licensing of new technologies and compositions of matter as appropriate. We intend to take advantage of any available data
6-K
EX-99.1
XRTX
XORTX Therapeutics Inc
3 Jan 24
XORTX Submits a New Patent for the Treatment of Chronic Kidney Disease
7:25am
based pharmacokinetic modeling of data from the XRX-OXY-101 clinical trial, and further innovation, resulted in a deeper understanding of how
424B5
XRTX
XORTX Therapeutics Inc
29 Nov 23
Prospectus supplement for primary offering
9:57pm
is not a reviewable transaction, to file a notification with Innovation, Science and Economic Development. The Investment Canada Act (Canada) generally
6-K
EX-99.1
yldvbj
7 Sep 23
XORTX Joins the Kidney Foundation and Kidney March
8:23am
6-K
EX-99.3
idu514 w6rbd
3 Apr 23
Consolidated Financial Statements
6:05am
6-K
EX-99.2
81o6tca ukve2
3 Apr 23
Consolidated Financial Statements
6:05am
424B3
5s2600fwsald2rku
14 Nov 22
Prospectus supplement
1:51pm
6-K
EX-99.2
u8hfswu05qrwc
14 Nov 22
Condensed Interim Consolidated Financial Statements
1:04pm
424B4
efl2oyd ej
5 Oct 22
Prospectus supplement with pricing info
5:24pm
POS AM
evdnz
29 Sep 22
Prospectus update (post-effective amendment)
9:49pm
F-1/A
hvo6k03q kkh2
21 Sep 22
Registration statement (foreign) (amended)
4:20pm
F-1
n857n6kx0cn2 d5h7dxq
8 Sep 22
Registration statement (foreign)
1:02pm
DRS
dad5a
15 Aug 22
Draft registration statement
12:00am
6-K
EX-99.2
5oygd33siburi6
11 Aug 22
Condensed Interim Consolidated Financial Statements
7:00am
6-K
EX-99.2
1tq7k 7ma6b
16 May 22
Condensed Interim Consolidated Financial Statements
7:25am
20-F
kv3p2blttn2ea1 k8mk
3 May 22
Annual report (foreign)
5:29pm